About this trial
By the end of 2019 a new coronavirus, named SARS-CoV-2, was discovered in patients with pneumonia in Wuhan, China. In the following weeks and months the virus spread globally, having a tremendous impact on global health and economy. To date, no vaccine or therapy is available. Severe courses of the infection not only affect the lungs, but also other organs like the heart, kidney, or liver. The lack of preexisting immunity might at least partially explain the affection of extra pulmonary organs not yet seen in infections due to other respiratory viruses. In this observational investigation the study group will follow up on patients that have been hospitalized due to a SARS-CoV-2 infection, and monitor sequelae in various organs, with an emphasis on the pulmo-cardiovascular system. Our that in some patients, organ damage will persist and require long-term medical care.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
hospitalization due to Sars-CoV-2 infection
Disqualifiers
under 18 years of age
Trial population
Adult patients that have been hospitalized due to Covid 19
Trial design
Cohort
Prospective
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Sequelae after COVID-19
Identify organ dysfunction after SARS-CoV-2 infections
Sponsors and contacts
Click on the lead sponsor to view all of their trials.